MedTrace Logo

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

NCT05188521 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-06-11

Study results available
· View outcomes & findings →

Summary

This research study is evaluating the safety and efficacy of Baricitinib in treating Cutaneous Lichen Planus (LP).

Conditions

  • Cutaneous Lichen Planus

Interventions

DRUG

Baricitinib (LY3009104) 2 mg

2 mg orally administered once daily for 16 weeks

DRUG

Baricitinib (LY3009104) 4 mg

4 mg orally administered once daily for 12 weeks

Sponsors & Collaborators

  • Aaron R. Mangold

    lead OTHER

Principal Investigators

  • Aaron R Mangold, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-11
Primary Completion
2023-05-17
Completion
2023-05-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05188521 on ClinicalTrials.gov